Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RORA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RORA LBD & DBD-LBD Recombinant Proteins (HEK293 expressed). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. | View RORA Products |
| Gene Delivery | RORA Promise-ORF / Lentivirus. Full-length ORF for stable reporter cell lines. CMV/EF1a promoter options. | View RORA Products |
| Benchmark Ab | Anti-RORA Control Recombinant Rabbit mAb. Validated for WB, IF, ChIP. | View RORA Products |
| Validator | RORA siRNA Set (3 unique sequences). >85% mRNA reduction guarantee for knockdown verification. | View RORA Products |
| Related Target A | RORC (RORγt). Critical isoform selectivity counter-screen; Th17 co-regulator. | View RORC Products |
| Related Target B | RORB (RORβ). CNS & circadian-related isoform for selectivity profiling. | View RORB Products |
| Related Target C | NR1D1 (REV-ERBα). Opposing circadian transcriptional repressor; combination target. | View NR1D1 Products |
| Critical Assay Challenge | TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (RORA vs RORC vs RORB) | Human RORA, RORC, RORB LBD proteins available (>95% purity), sequence verified by mass spec. |
| Inverse Agonist Binding & Coactivator Displacement | High-purity RORA LBD suitable for TR-FRET and Fluorescence Polarization assays. |
| Full-Length Functional Validation | Lentiviral RORA ORF particles for stable reporter cell line generation. |
| DNA Binding Domain Integrity | DBD-specific construct (aa 89-170) with verified zinc finger folding. |
| Off-Target & Specificity Controls | Validated RORA siRNA set for genetic target engagement confirmation. |
Live RORA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RORA-targeted therapeutics is intensifying, with drug discovery efforts pivoting from pan-ROR approaches toward isoform-selective inverse agonists. RORA (RAR-related Orphan Receptor Alpha) is a critical nuclear receptor modulating lipid metabolism, circadian rhythms, and immunity. Major players such as Takeda, AbbVie, and Aurigene are focusing on small molecule inverse agonists and agonists. The next wave of R&D targets highly selective RORA modulators and PROTAC degraders to address autoimmune, metabolic, and CNS disorders without off-target effects associated with pan-ROR modulation. Emerging modalities include PROTACs for cancer metabolism and gene therapy for rare metabolic conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inverse Agonist | Takeda, AbbVie, Aurigene, Scripps Research | Psoriasis, Rheumatoid Arthritis, MS, Asthma, IBD | Isoform Selectivity Panel (RORA vs RORC vs RORB LBD proteins) |
| PROTAC/Degrader | Emerging Biotechs | Cancer / Metabolic, Breast Cancer | Degradation Assay (Full-length RORA protein, specific antibodies, cell lines) |
| Circadian/Metabolic Modulator | Chronobiology Biotechs, Academic Consortia | Metabolic Syndrome, NASH, Sleep Disorders | Clock Gene Reporter Assay (Lentiviral RORA ORF stable lines) |
| Gene Therapy | Research Institutes | Rare Metabolic Disorders | Functional Overexpression Systems (ORF lentivirus) |